Lexicon Genetics and Abgenix to Jointly Validate Drug Targets | GenomeWeb

NEW YORK, Jan 3 – Lexicon Genetics has agreed to use its knockout mouse technology to validate drug targets for Abgenix’ human antibody therapeutics, the companies announced Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.